A need for further investigation for fluorescence image-guided surgery in breast conserving surgery (BCS) has arisen following the results obtained from a phase I feasibility breast cancer trial (BIRDYE study: ABR NL 37479.042011). The aim of this study is to define the optimal dose of the fluorescent tracer Bevacizumab-IRDye800CW for intraoperative delineation of breast cancer tissue using the improved and optimized fluorescent tracer and camera system.
Study Type
INTERVENTIONAL
Allocation
NON_RANDOMIZED
Purpose
DIAGNOSTIC
Masking
NONE
Enrollment
26
three days prior to surgery bevacizumab-800CW will be administered
University Medical Center Groningen
Groningen, Provincie Groningen, Netherlands
Tumor-to-background ratio
Time frame: day 3
Number of participants with treatment-related adverse events
Time frame: up to two weeks
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.